Clinical Trial Update: (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating (neo)adjuvant BRAF/MEK inhibition in pN1c melanoma with in-transit metastases. Current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BRAF/MEK inhibitors

Snippet

Sponsor: Leiden University Medical Center | Conditions: Melanoma Stage III, In-Transit Metastasis of Cutaneous Melanoma | Phase 2 | Status: UNKNOWN